On January 2, 2019 Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or the "Company") reported that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the 37th Annual J.P. Morgan Healthcare Conference as follows (Press release, Eagle Pharmaceuticals, JAN 2, 2019, View Source [SID1234532373]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Date: Wednesday, January 9, 2019
Time: 2:30 p.m. Pacific Standard Time
Location: Westin St. Francis Hotel, San Francisco
Webcast:

View Source

The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Company’s website at www.eagleus.com, under the Investors Section.

On January 2, 2018 Alkermes plc (Nasdaq: ALKS) reported that its corporate presentation will be webcast live at the 37th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 8, 2019 at 9:30 a.m. PT (12:30 p.m. ET/5:30 p.m. GMT) from the Westin St. Francis Hotel in San Francisco (Press release, Alkermes, JAN 2, 2019, View Source;p=RssLanding&cat=news&id=2381873 [SID1234532371]). The presentation will be followed by a question and answer session that will begin at 10:00 a.m. PT (1:00 p.m. ET/6:00 p.m. GMT). A webcast of both the presentation and question and answer session may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes’ website at www.alkermes.com

On January 2, 2019 Bausch Health Companies Inc. (NYSE/TSX: BHC) reported that Joseph C. Papa, chairman and chief executive officer, is scheduled to present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, Jan. 7, 2019 at 2:00 p.m. PST (5:00 p.m. EST) (Press release, Valeant, JAN 2, 2019, View Source [SID1234532370]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast and audio archive of the event will be available on the Investor Relations page of the Bausch Health Companies Inc. web site at: View Source

On January 2, 2019 Veracyte, Inc. (Nasdaq: VCYT) reported that Bonnie H. Anderson, chairman and chief executive officer, is scheduled to present at the 37th Annual J.P. Morgan Healthcare Conference on Thursday, January 10, 2019 at 11:30 a.m. PST (2:30 p.m. EST) followed by a question and answer (Q&A) session at 12:00 p.m. PST (3:00 p.m. EST) (Press release, Veracyte, JAN 2, 2019, View Source [SID1234532369]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Links to the live webcasts of the presentation and Q&A session, as well as the replays of these events, will be available via Veracyte’s website at View Source Replays of the webcasts will be available for 90 days following the conclusion of the live broadcasts.

On January 2, 2019 Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, reported that CEO Stéphane Bancel will present an update on the Company and its pipeline of mRNA development programs at this year’s 37th annual J.P. Morgan Healthcare Conference (Press release, Moderna Therapeutics, JAN 2, 2019, View Source [SID1234532368]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mr. Bancel’s presentation will take place on Tuesday, January 8, 2019 at 10:30 a.m. PT in the Colonial Room at The Westin St. Francis Hotel in San Francisco. The presentation will be followed by a question and answer session. A live webcast of both the presentation and question and answer session can be accessed on the investors section of Moderna’s website at investors.modernatx.com. A replay of the webcast also will be archived on Moderna’s website for up to 30 days following the presentation.